Aratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per Share

Wall Street brokerages expect that Aratana Therapeutics Inc (NASDAQ:PETX) will post ($0.23) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Aratana Therapeutics’ earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.27). Aratana Therapeutics posted earnings of ($0.35) per share during the same quarter last year, which indicates a positive year over year growth rate of 34.3%. The business is scheduled to report its next quarterly earnings report on Monday, March 12th.

According to Zacks, analysts expect that Aratana Therapeutics will report full-year earnings of ($1.03) per share for the current fiscal year, with EPS estimates ranging from ($1.07) to ($0.99). For the next financial year, analysts expect that the firm will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.72) to ($0.10). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Aratana Therapeutics.

A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 18th. HC Wainwright assumed coverage on shares of Aratana Therapeutics in a report on Friday, November 17th. They issued a “buy” rating and a $10.00 price objective on the stock. Jefferies Group set a $9.00 price objective on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 16th. Stifel Nicolaus restated a “hold” rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a report on Monday, December 18th. Finally, CL King assumed coverage on shares of Aratana Therapeutics in a report on Wednesday, December 27th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.55.

Aratana Therapeutics (NASDAQ PETX) traded down $0.27 during mid-day trading on Monday, hitting $4.10. 549,700 shares of the company’s stock were exchanged, compared to its average volume of 496,303. Aratana Therapeutics has a 12-month low of $3.91 and a 12-month high of $7.67. The stock has a market capitalization of $176.30, a PE ratio of -2.83 and a beta of 3.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08.

In other news, CEO Peter Steven St sold 19,367 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the transaction, the chief executive officer now owns 672,259 shares in the company, valued at $3,206,675.43. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Craig A. Tooman sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total transaction of $158,100.00. Following the completion of the transaction, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,056,399 shares of company stock worth $6,087,271. Insiders own 5.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Voya Investment Management LLC increased its stake in shares of Aratana Therapeutics by 22.7% in the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 3,610 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Aratana Therapeutics by 7.2% in the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 1,709 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Aratana Therapeutics by 6.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 1,875 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Aratana Therapeutics by 25.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 6,898 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Aratana Therapeutics by 26.1% in the 2nd quarter. Alliancebernstein L.P. now owns 49,350 shares of the biopharmaceutical company’s stock worth $357,000 after acquiring an additional 10,200 shares during the last quarter. Hedge funds and other institutional investors own 73.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/aratana-therapeutics-inc-petx-expected-to-post-earnings-of-0-23-per-share.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply